Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus

Type 2 diabetes mellitus (T2DM) and other metabolic disorders are often silent and go unnoticed in patients because of the lack of suitable prognostic and diagnostic markers. The current therapeutic regimens available for managing T2DM do not reverse diabetes; instead, they delay the progression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Roham, Pratiksha H., Save, Shreyada N., Sharma, Shilpy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2022
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463490/
https://www.ncbi.nlm.nih.gov/pubmed/36105173
http://dx.doi.org/10.1016/j.jpha.2022.04.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463490/
https://www.ncbi.nlm.nih.gov/pubmed/36105173
http://dx.doi.org/10.1016/j.jpha.2022.04.001

Ejemplares similares